AbbVie Inc (ABBV)vsLegend Biotech Corp (LEGN)
ABBV
AbbVie Inc
$230.01
+0.06%
HEALTHCARE · Cap: $391.50B
LEGN
Legend Biotech Corp
$29.34
-4.62%
HEALTHCARE · Cap: $6.66B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5415% more annual revenue ($62.82B vs $1.14B). ABBV leads profitability with a 5.8% profit margin vs -22.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
LEGN
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$230.01
$83.79 premium
Intrinsic value data unavailable for LEGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 56.5% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
ROE of -25.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : LEGN
The strongest argument for LEGN centers on Revenue Growth. Revenue growth of 56.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : LEGN
The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while LEGN is a hypergrowth play — different risk/reward profiles.
LEGN carries more volatility with a beta of 0.35 — expect wider price swings.
LEGN is growing revenue faster at 56.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Legend Biotech Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?